Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.

Von Hoff, D D; Green, S; Surwit, E A; Hannigan, E V; Alberts, D S

Von Hoff, D D; Green, S; Surwit, E A; Hannigan, E V; Alberts, D S.

Von Hoff DD; University of Texas Health Science Center, San Antonio 78284-7884.

Am J Clin Oncol ; 13(5): 433-5, 1990 Oct.

Article en En | MEDLINE | ID: mdl-1699401

ABSTRACT

ABSTRACT

Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.

Asunto(s)

Antimetabolitos Antineoplásicos/uso terapéutico; Neoplasias del Cuello Uterino/tratamiento farmacológico; Fosfato de Vidarabina/análogos & derivados; Adulto; Anciano; Anemia/inducido químicamente; Antimetabolitos Antineoplásicos/efectos adversos; Evaluación de Medicamentos; Femenino; Humanos; Leucopenia/inducido químicamente; Persona de Mediana Edad; Estados Unidos; Fosfato de Vidarabina/efectos adversos; Fosfato de Vidarabina/uso terapéutico

Search on Google

Imprimir

XML

PubMed Links

Banco de datos: MEDLINE Asunto principal: Fosfato de Vidarabina / Neoplasias del Cuello Uterino / Antimetabolitos Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Middle aged País como asunto: America do norte Idioma: En Año: 1990 Tipo del documento: Article

Search on Google

Imprimir

XML

PubMed Links